Last reviewed · How we verify
ABITUZUMAB
Abituzumab is being studied as a treatment for different cancers, including those that have spread to the liver.
Abituzumab is an agent being studied in various cancers. Clinical trials are evaluating its use in colorectal, ovarian, and prostate cancers with liver metastases. It is being investigated in combination with other therapies like cetuximab and FOLFIRI.
At a glance
| Generic name | ABITUZUMAB |
|---|---|
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Abituzumab is being evaluated for its potential to treat cancers that have spread to the liver. Clinical trials are underway to determine how well it works in different types of cancer. Researchers are also looking at combining it with existing treatments to see if it can improve outcomes.
Approved indications
Common side effects
Key clinical trials
- A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitia (Phase 2)
- A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, PD and PK of EMD 525797 Using DCE-MRI as a PK Measure of Response in Colorectal and Ovarian Cancer Patients With L (Phase 1)
- AMELION: A Randomized, Double Blinded, Phase 2, Efficacy and Safety Study of Abituzumab (EMD 525797) in Combination With Cetuximab and FOLFIRI Versus Placebo in Combination With Cetuximab and FOLFIRI (Phase 2)
- A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prost (Phase 2)
- Phase I, Open-label Study to Investigate Safety, Tolerability, PK, and PD of EMD 525797 After Single and Repeated Dosing at Different Dose Levels in Subjects With Hormone-resistant Prostate Cancer Wit (Phase 1)
- An Open-label, Randomized, Controlled, Multicenter, Phase I/II Trial Investigating 2 EMD 525797 Doses in Combination With Cetuximab and Irinotecan Versus Cetuximab and Irinotecan Alone, as Second-line (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABITUZUMAB CI brief — competitive landscape report
- ABITUZUMAB updates RSS · CI watch RSS
- portfolio CI